Reporting from ASCO 2023, Thomas John discusses the results from the ADAURA study of adjuvant osimertinib in patients with resected EGFR mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC).
Abstract: LBA3 - Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC), presented by Roy Herbst. Simultaneously published in The New England Journal of Medicine.
The ESMO Educational Videos series features renowned experts in oncology sharing their knowledge on a variety of subjects. Full series here oncologypro.esmo.org/oncology...
Produced by the European Society for Medical Oncology
oncologypro.esmo.org